Rodman & Renshaw maintained its SuperGen (SUPG) Market Outperform rating and $5 price target in a research report published today.
In the report, Rodman & Renshaw states, "We believe that the combined companies' pipeline could be valued at par with the average of a comparable group of oncology drug developers, which trade at an enterprise value of slightly greater than $300MM."
Shares of SuperGen were trading at $2.85 at the time of posting, down 5.94% from Tuesday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in